

## FORM 7

### MONTHLY PROGRESS REPORT

**Name of Listed Issuer:** The Yield Growth Corp. (the "Issuer").

**Trading Symbol:** BOSS

**Number of Outstanding Listed Securities:** 87,054,140 common shares (plus 40,796,476 common shares reserved for issuance in the form of 29,902,976 warrants and 10,893,500 options)

**Date:** March 1, 2019

#### **Report on Business**

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On February 1, 2019, the Issuer began trading its common shares on the OTCQB Venture Market in the United States under the ticker symbol "BOSQF". The Issuer's common shares continue to trade on the Canadian Securities Exchange under the ticker symbol "BOSS" and on the Frankfurt Exchange under the ticker symbol "YG3".

On February 5, 2019, the Issuer completed the acquisition of eight wellness beverage formulas designed to be infused with CBD and THC and one capsule product intended to treat hangovers. The Issuer issued 200,000 shares and 200,000 warrants to purchase shares at \$0.60 per share pursuant to the acquisition and is obligated to pay net revenues from sales of 2%.

On February 7, 2019, the Issuer announced that its e-commerce platform will now sell its Urban Juve Cannabis Sativa hemp root oil-based products in the United States thanks to the adoption of the 2018 U.S. Farm Bill.

On February 12, 2019, the Issuer finalized product formulations and selected all THC and CBD strains for its first 9 products to launch in Oregon through a 400-retail distribution network. Pursuant to its agreement with a licensed cannabis processing facility in Oregon, the Issuer's subsidiary, UJ Topicals' branded products will be launching in the Oregon legal cannabis market. The products include CBD and THC oils, Analgesic Topical Gel with THC and CBD, Pain Balm with THC and CBD, Massage Oil with THC and CBD, and 3 types of capsules containing THC and Ayurvedic herbal formulations, blended with ingredients that have been used to treat arthritis and chronic pain. All of the cannabis topical products have been formulated based on Urban Juve's proprietary formulas, for which 11 provisional patents have been filed in the United States.

On February 14, 2019, the Issuer announced six new products under the Urban Juve brand: Vitalize Face Mist, Balance Face Mist, Align Face Mist, Vitalize Daily Ritual Oil, Balance Daily Ritual Oil, and Align Daily Ritual Oil. The six new products complete Phase One of the Urban Juve unisex product line, bringing the total number of separate

product SKU's to 11. Phase two is expected to begin in June 2019 and will include 10 more personal care products.

On February 15, 2019, the Issuer announced that its common shares received The Depository Trust Company ("DTC") full service eligibility in the United States. The Issuer's identifier in the United States is "BOSQF". DTC settlement services provide a more efficient and lower cost settlement process for investors and brokers trading Canadian securities in the United States. DTC eligibility enables shares of the Issuer to be distributed, settled and serviced through DTC's automated processes, thereby taking advantage of the efficiencies created in the electronic method of clearing securities and the resulting cost benefits that DTC provides through accelerated settlement processes.

On February 19, 2019, the Issuer announced it had received over \$3,600,000 in warrant and option exercises in the first two weeks of February 2019.

On February 21, 2019, the Issuer announced the completion of the formulations for 10 new products to be infused with cannabinoids: four facial skin care products, four essential oil wellness blends, and two foot creams. Urban Juve has developed four new skin care products that it intends to add to the Urban Juve product line later this year. These include an eye cream, a makeup remover, a liquid face cleanser, and facial cleanser pads. Urban Juve has also developed four exotic essential oil wellness blends, all containing hemp root oil. They are tentatively entitled "Energy Boost", "Headache", "Sleep", and "Stress". Each of the formulas are designed to be easily blended with THC and CBD oils. UJ Topicals has developed two foot creams, with hemp root oil, clay and essential oils, that are created to be infused with cannabinoids. One cream is intended to be infused with CBD and the other cream is intended to be infused with THC.

On February 26, 2019, the Issuer announced that its Urban Juve unisex lip balm and anti-aging serum, both of which are infused with hemp root oil extracted using the Issuer's patent pending method, were selected for inclusion in gift bags given to the Awards presenters during a pre-Oscars event at the Four Seasons Hotel Los Angeles in Beverly Hills.

On February 28, 2019, the Issuer announced its subsidiary, Urban Juve, registered for sale with Health Canada three Lip Glosses with tint names "Love", "Pleasure", and "Serenity". Each contains a unique blend of camelia, jojoba, avocado, castor, and coconut oils designed to moisturize the lips to make them look full and supple. Cannabis sativa hemp seed oil and hemp root oil extracted using Urban Juve's proprietary patent pending technology, are included as ingredients intended to give extra moisture and hydration for lusher looking lips that stay smooth.

**2. Provide a general overview and discussion of the activities of management.**

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see Item 1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

8. Describe the acquisition of new customers or loss of customers.

Please see Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Please see Item 1 above.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

**12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

**13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None.

**14. Provide details of any securities issued and options or warrants granted.**

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds <sup>(1)</sup></b>
Common Shares	30,000	February 1, 2019: Shares were issued pursuant to an option exercise at \$0.10 per common share	General working capital
Common Shares	200,000	February 1, 2019: Shares were issued pursuant to an option exercise at \$0.40 per common share	General working capital
Units	200,000	February 5, 2019: Units issued at a deemed price of \$0.50 per unit pursuant to an Acquisition Agreement whereby 200,000 units were issued, each unit consisting of one common share and one share purchase warrant exercisable at a price of \$0.60 per share for a period of one year from the date of issuance	Not applicable, units were issued at a deemed price pursuant to an acquisition agreement
Common Shares	154,411	February 5, 2019: Shares were issued pursuant to a warrant exercise at \$0.40 per common share	General working capital
Common Shares	375,720	February 5, 2019: Shares were issued pursuant to a warrant exercise at \$0.50 per common share	General working capital
Common Shares	385,000	February 5, 2019: Shares were issued pursuant to a warrant	General working capital

		exercise at \$0.70 per common share	
Units	1,000,000	February 6, 2019: Units issued at a deemed price of \$0.40 per unit pursuant to a Debt Conversion Agreement whereby 1,000,000 units were issued, each unit consisting of one common share and one share purchase warrant exercisable at a price of \$0.50 per share for a period of six months from the date of issuance	Not applicable, units were issued at a deemed price pursuant to a Debt Conversion Agreement
Common Shares	3,000	February 7, 2019: Shares were issued pursuant to a warrant exercise at \$0.50 per common share	General working capital
Common Shares	1,876,666	February 7, 2019: Shares were issued pursuant to a warrant exercise at \$0.70 per common share	General working capital
Common Shares	70,000	February 8, 2019: Shares were issued pursuant to a warrant exercise at \$0.70 per common share	General working capital
Common Shares	2,177,180	February 13, 2019: Shares were issued pursuant to a warrant exercise at \$0.70 per common share	General working capital
Common Shares	155,882	February 15, 2019: Shares were issued pursuant to a warrant exercise at \$0.40 per common share	General working capital
Units	191,134	February 20, 2019: Units issued at a deemed price of \$0.70 per unit pursuant to a Debt Conversion Agreement whereby 191,134 units were issued, each unit consisting of one common share and one share purchase warrant exercisable at a price of \$0.80 per share for a period of six months from the date of issuance	Not applicable, units were issued at a deemed price pursuant to a Debt Conversion Agreement

**FORM 7 – MONTHLY PROGRESS REPORT**

January 2015

Page 5

Common Shares	75,000	February 21, 2019: Shares were issued pursuant to an option exercise at \$0.50 per common share	General working capital
Common Shares	21,400	February 21, 2019: Shares were issued pursuant to a warrant exercise at \$0.50 per common share	General working capital
Common Shares	4,500	February 22, 2019: Shares were issued pursuant to a warrant exercise at \$0.50 per common share	General working capital
Common Shares	131,750	February 26, 2019: Shares were issued pursuant to a warrant exercise at \$0.50 per common share	General working capital
Units	125,714	February 20, 2019: Units issued at a deemed price of \$0.70 per unit pursuant to a Debt Conversion Agreement whereby 125,714 units were issued, each unit consisting of one common share and one share purchase warrant exercisable at a price of \$0.80 per share for a period of six months from the date of issuance	Not applicable, units were issued at a deemed price pursuant to a Debt Conversion Agreement

(1) State aggregate proceeds and intended allocation of proceeds.

**15. Provide details of any loans to or by Related Persons.**

None.

**16. Provide details of any changes in directors, officers or committee members.**

None.

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On June 20, 2018, the Government of Canada held the final vote on Bill C-45, the Cannabis Act, in the Senate. The Cannabis Act passed in the Senate and received Royal Assent on June 21, 2018. The Cannabis Act came into force on October 17, 2018, recreational cannabis is now available to legal adults (aged 18 or 19 depending on the province or territory) for purchase, growth, or use in limited quantities. The Government of Canada is anticipated to pass legislation in late 2019 to approve and regulate the sale of Cannabis topical and edible products.

## **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

**Dated** March 1, 2019.

Penny Green  
Name of Director or Senior Officer

"Penny Green"  
Signature

Chief Executive Officer  
Official Capacity

<b><i>Issuer Details</i></b> <b>Name of Issuer</b> The Yield Growth Corp.	<b>For Month End</b> February 2019	<b>Date of Report</b> <b>YY/MM/DD</b> 19/03/01
<b>Issuer Address</b> Suite 200, 1238 Homer Street		
<b>City/Province/Postal Code</b> Vancouver, British Columbia V6B 2Y5	<b>Issuer Fax No.</b> N/A	<b>Issuer Telephone No.</b> 833.514.2677
<b>Contact Name</b> Penny Green	<b>Contact Position</b> President, CEO, and Director	<b>Contact Telephone No.</b> 833.514.2677
<b>Contact Email Address</b> <a href="mailto:penny@yieldgrowth.com">penny@yieldgrowth.com</a>	<b>Web Site Address</b> <a href="http://www.yieldgrowth.com">www.yieldgrowth.com</a>	